Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.9K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.9K
Combinatorial Gene Control02:33

Combinatorial Gene Control

9.4K
Combinatorial gene control is the synergistic action of several transcriptional factors to regulate the expression of a single gene. The absence of one or more of these factors may lead to a significant difference in the level of gene expression or repression.
The expression of more than 30,000 genes is controlled by approximately 2000-3000 transcription factors. This is possible because a single transcription factor can recognize more than one regulatory sequence. The specificity in gene...
9.4K
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

3.8K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.9K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.9K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Enhancer of zeste 2 polycomb repressive complex 2 subunit overexpression suppresses apoptosis in canine T-cell lymphoma: an <i>in vitro</i> functional analysis.

Frontiers in veterinary science·2026
Same author

Niche-targeted therapy via YAP/TAZ activation enhances hematopoietic regeneration.

Blood·2026
Same author

Transferrin Receptor Marks a Foxp3-Low Treg-like Inflammatory T Cell Subset Associated with Disease Severity in HAM/TSP.

Pathogens (Basel, Switzerland)·2026
Same author

Polycomb repressive complex 2 insufficiency underlies myeloid leukemia in Down syndrome.

Blood·2026
Same author

Non-necroptotic MLKL function damages mitochondria and promotes hematopoietic stem cell aging.

Nature communications·2026
Same author

Impact of sentinel lymph node biopsy versus axillary lymph node dissection on shoulder range of motion in early rehabilitation after breast cancer surgery.

Breast cancer (Tokyo, Japan)·2026

相关实验视频

Updated: Jan 7, 2026

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes
10:26

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes

Published on: January 16, 2015

8.8K

多镇压复合体作为血液恶性瘤治疗点

Makoto Yamagishi1, Atsushi Iwama2, Issay Kitabayashi2

  • 1Laboratory of Viral Oncology and Genomics, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan; Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Experimental hematology
|December 24, 2025
PubMed
概括

多胞体抑制复合体 (PRC1和PRC2) 调节基因表达,对于造血干细胞维护至关重要. 异常的PRC1/2活性驱动血液恶性瘤,但双EZH1/2抑制剂显示出有前途.

关键词:
多重复合镇压复合体 镇压复合体通过乙化处理.表观遗传调节 表观遗传调节甲基化处理的方法

更多相关视频

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
09:16

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Published on: September 1, 2019

8.0K
Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

4.7K

相关实验视频

Last Updated: Jan 7, 2026

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes
10:26

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes

Published on: January 16, 2015

8.8K
Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
09:16

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Published on: September 1, 2019

8.0K
Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

4.7K

科学领域:

  • 表观遗传学和转录的调节.
  • 血液形成和干细胞生物学
  • 癌症表观遗传学和治疗方法

背景情况:

  • 多组组 (PcG) 蛋白质,组织成PRC1和PRC2复合体,通过基因素修饰来控制遗传基因沉默.
  • PRC1和PRC2在造血干细胞 (HSC) 的自我更新和谱系规范中发挥着关键作用.
  • PRC1/2组件的失调,包括EZH2和BCOR中的突变,与AML,MDS和淋巴瘤等血液恶性瘤有关.

研究的目的:

  • 审查PRC1和PRC2在正常血液形成中的作用以及它们在血液恶性瘤中的参与.
  • 讨论PRC2的治疗向,包括EZH2-选择性和双EZH1/2抑制剂,在淋巴瘤瘤中.
  • 突出PRC2向治疗的挑战,如耐药性机制,以及双重抑制剂的潜力.

主要方法:

  • 文献综述和对Polycomb组蛋白在血液形成和癌症中的现有研究的综合.
  • 分析PRC1和PRC2在转录抑制和疾病中的作用机制.
  • 评估涉及EZH2和双EZH1/2抑制剂的临床数据和治疗策略.

主要成果:

  • PRC1和PRC2对于高血小板维护至关重要,它们的异常功能驱动各种血液癌症.
  • 升高的H3K27me3是淋巴瘤瘤中常见的表观遗传特征,使PRC2成为一个可行的治疗点.
  • 双 EZH1/2 抑制剂,如 valemetostat,通过克服对 EZH2 特定药物的耐药性来证明在治疗 ATL 和 PTCL 的有效性.

结论:

  • 向表观基因组,特别是PRC2,是治疗血液性恶性瘤的一个有希望的策略.
  • 双 EZH1/2 抑制剂提供了潜在的治疗优势比EZH2-选择性抑制剂由于更广泛的目标参与.
  • 继续开发双EZH1/2抑制剂是必要的,以克服治疗耐药性和改善淋巴瘤瘤患者的治疗结果.